Abstract

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study

J Crohns Colitis. 2021 Dec 18;15(12):2001-2010. doi: 10.1093/ecco-jcc/jjab093.

 

Marc Ferrante 1Brian G Feagan 2Julián Panés 3Filip Baert 4Edouard Louis 5Olivier Dewit 6Arthur Kaser 7W Rachel Duan 8Yinuo Pang 8Wan-Ju Lee 8Dawn Gustafson 8Xiaomei Liao 8Kori Wallace 8Jasmina Kalabic 9Geert R D'Haens 10

 
     

Author information

1University Hospitals Leuven, KU Leuven, Leuven, Belgium.

2University of Western Ontario, London, ON, Canada.

3Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.

4AZ Delta Roeselare-Menen, Roeselare, Belgium.

5University of Liège and CHU, Liège, Belgium.

6Cliniques Universitaires Saint-Luc, Brussels, Belgium.

7University of Cambridge and Cambridge University Hospitals - Addenbrooke's Hospital, Cambridge, UK.

8AbbVie Inc., North Chicago, IL, USA.

9AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.

10Amsterdam University Medical Center, Amsterdam, Netherlands.

Abstract

Background and aims: Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn's disease. This open-label extension investigated the long-term safety, pharmacokinetics, immunogenicity and efficacy of risankizumab in responders to risankizumab in the parent phase 2 study.

Methods: Enrolled patients had achieved clinical response [decrease in Crohn's Disease Activity Index from baseline ≥100] without clinical remission [Crohn's Disease Activity Index <150] at Week 26, or clinical response and/or remission at Week 52 in the parent phase 2 study and received open-label subcutaneous risankizumab 180 mg every 8 weeks.

Results: Sixty-five patients were enrolled, including four who had lost response in the parent study and were first reinduced with risankizumab 600 mg every 4 weeks [three infusions]. Patients received risankizumab for a median of 33 months [total: 167.0 patient-years]. The rate of serious adverse events was 24.6 events/100 patient-years; the majority were gastrointestinal in nature. Rates of serious infections, opportunistic infections and fungal infections were 4.2, 1.8, and 6.6 events/100 patient-years, respectively. No deaths, malignancies, adjudicated major adverse cardiovascular events, latent/active tuberculosis or herpes zoster were reported. Treatment-emergent anti-drug antibodies developed in eight patients [12.3%]; none were neutralizing. Efficacy outcomes were maintained during the study, including the proportions of patients [observed analysis] with clinical remission [>71%] and endoscopic remission [>42%].

Conclusions: Long-term maintenance treatment with subcutaneous risankizumab 180 mg every 8 weeks was well tolerated by patients with Crohn's disease, with no new safety signals. Clinical trial registration number: NCT02513459.

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.